Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM. Martin NE, et al. Among authors: deutsch p. Clin Cancer Res. 2004 Aug 15;10(16):5447-54. doi: 10.1158/1078-0432.CCR-04-0248. Clin Cancer Res. 2004. PMID: 15328183 Clinical Trial.
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K, Koblan KS, Lee Y, Mosser S, Motzel SL, Abbruzzese JL, Fuchs CS, Rowinsky EK, Rubin EH, Sharma S, Deutsch PJ, Mazina KE, Morrison BW, Wildonger L, Yao SL, Kohl NE. Lobell RB, et al. Among authors: deutsch pj. Mol Cancer Ther. 2002 Jul;1(9):747-58. Mol Cancer Ther. 2002. PMID: 12479371
Indinavir and rifabutin drug interactions in healthy volunteers.
Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Kraft WK, et al. J Clin Pharmacol. 2004 Mar;44(3):305-13. doi: 10.1177/0091270003262807. J Clin Pharmacol. 2004. PMID: 14973305 Clinical Trial.
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL. DiPaola RS, et al. Among authors: deutsch p. J Clin Oncol. 2002 Apr 1;20(7):1874-9. doi: 10.1200/JCO.2002.07.001. J Clin Oncol. 2002. PMID: 11919247 Clinical Trial.
Pharmacokinetics of ertapenem in healthy young volunteers.
Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, Rogers JD. Majumdar AK, et al. Among authors: deutsch p. Antimicrob Agents Chemother. 2002 Nov;46(11):3506-11. doi: 10.1128/AAC.46.11.3506-3511.2002. Antimicrob Agents Chemother. 2002. PMID: 12384357 Free PMC article. Clinical Trial.
Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Stone JA, et al. Antimicrob Agents Chemother. 2004 Nov;48(11):4306-14. doi: 10.1128/AAC.48.11.4306-4314.2004. Antimicrob Agents Chemother. 2004. PMID: 15504857 Free PMC article. Clinical Trial.
113 results